Molnupiravir provides little benefit in vaccinated adults with COVID-19

Area of Science:

• Infectious Diseases
• Virology
• Clinical Trials

Background:

• COVID-19 remains a significant global health concern, particularly for individuals at high risk of severe outcomes.
• Early antiviral treatment is a key strategy to mitigate COVID-19 severity.
• Molnupiravir is an oral antiviral agent approved for treating mild-to-moderate COVID-19 in at-risk adults.

Purpose of the Study:

• To evaluate the efficacy of molnupiravir plus usual care compared to usual care alone in reducing adverse outcomes in high-risk adults with COVID-19.
• To assess the impact of early molnupiravir treatment on hospitalization and mortality rates.

Main Methods:

• An open-label, platform-adaptive, randomized controlled trial (PANORAMIC) involving adults with COVID-19 at increased risk of adverse outcomes.
• Participants received either molnupiravir plus usual care or usual care alone.
• Primary outcome was hospitalization or death within 28 days of randomization.

Main Results:

• Molnupiravir plus usual care did not result in a statistically significant reduction in hospitalizations or deaths compared to usual care alone (9.7% vs 10.1%).
• Symptomatic recovery occurred slightly faster in the molnupiravir group, but this was not a primary endpoint.
• Adverse events were similar between the two groups.

Conclusions:

• Early treatment with molnupiravir in high-risk COVID-19 patients did not significantly decrease the risk of hospitalization or death.
• The findings suggest that molnupiravir may not be a preferred antiviral strategy for this patient group.
• Further research may be needed to identify optimal early treatment regimens for COVID-19 in at-risk populations.